Publication: Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes.
Loading...
Identifiers
Date
2018-04-05
Authors
Martinez-Losada, Carmen
Serrano-Lopez, Juana
Serrano-Lopez, Josefina
Noguera, Nelida I
Garza, Eduardo
Piredda, Liliana
Lavorgna, Serena
Consalvo, Maria Antonietta Irno
Ottone, Tiziana
Alfonso, Valentina
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Fondazione Ferrata Storti
Abstract
Acute myeloid leukemia (AML) is a dynamic disease caused by accumulating, somatically acquired driver mutations generating branching competing clones.1 In favorable-risk AML, high resolution genomic profiling by single nucleotide polymorphism array analysis of paired diagnostic-relapse NPM1mut and CBF AML samples revealed increased genomic complexity at relapse but
most patients retained founding mutations.2,3 Furthermore, it has been extensively reported that phe notypic changes are commonly found at relapse in AML patients. It seems plausible that clonal evolution could be
reflected in the phenotypic shifts of AML blast cells found at relapse, although the correlation with genetic clonal evolution has not been established
Description
MeSH Terms
Humans
Leukemia, Myeloid, Acute
Mutation
Nuclear Proteins
Nucleophosmin
Phenotype
Prognosis
Recurrence
Leukemia, Myeloid, Acute
Mutation
Nuclear Proteins
Nucleophosmin
Phenotype
Prognosis
Recurrence
DeCS Terms
Fenotipo
Leucemia mieloide aguda
Mutación
Nucleofosmina
Pronóstico
Proteínas nucleares
Recurrencia
Leucemia mieloide aguda
Mutación
Nucleofosmina
Pronóstico
Proteínas nucleares
Recurrencia
CIE Terms
Keywords
Biomarkers, Tumor, Clonal Evolution, DNA Mutational Analysis, Genetic Association Studies, Genome-Wide Association Study
Citation
Martínez-Losada C, Serrano-López J, Serrano-López J, Noguera NI, Garza E, Piredda L, et al. Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes. Haematologica. 2018 Sep;103(9):e400-e403